Search

Your search keyword '"Fontana, Elisa"' showing total 277 results
Start Over Author "Fontana, Elisa"
277 results on '"Fontana, Elisa"'

2. PBRM1 mutations might render a subtype of biliary tract cancers sensitive to drugs targeting the DNA damage repair system

Author

Zimmer, Kai, Kocher, Florian, Untergasser, Gerold, Kircher, Brigitte, Amann, Arno, Baca, Yasmine, Xiu, Joanne, Korn, W. Micheal, Berger, Martin D., Lenz, Heinz-Josef, Puccini, Alberto, Fontana, Elisa, Shields, Anthony F., Marshall, John L., Hall, Michael, El-Deiry, Wafik S., Hsiehchen, David, Macarulla, Teresa, Tabernero, Josep, Pichler, Renate, Khushman, Moh’d, Manne, Upender, Lou, Emil, Wolf, Dominik, Sokolova, Viktorija, Schnaiter, Simon, Zeimet, Alain G., Gulhati, Pat, Widmann, Gerlig, and Seeber, Andreas

Published
2023
Full Text
View/download PDF

3. Camonsertib in DNA damage response-deficient advanced solid tumors: phase 1 trial results

Author

Yap, Timothy A., Fontana, Elisa, Lee, Elizabeth K., Spigel, David R., Højgaard, Martin, Lheureux, Stephanie, Mettu, Niharika B., Carneiro, Benedito A., Carter, Louise, Plummer, Ruth, Cote, Gregory M., Meric-Bernstam, Funda, O’Connell, Joseph, Schonhoft, Joseph D., Wainszelbaum, Marisa, Fretland, Adrian J., Manley, Peter, Xu, Yi, Ulanet, Danielle, Rimkunas, Victoria, Zinda, Mike, Koehler, Maria, Silverman, Ian M., Reis-Filho, Jorge S., and Rosen, Ezra

Published
2023
Full Text
View/download PDF

6. Development of biomarker assays to dissect subtype-specific heterogeneity and anti-EGFR treatment response in colorectal cancer

Author

Fontana, Elisa and Sadanandam, A.

Subjects
Colorectal Cancer--Therapy, Colorectal Cancer--Genetics, Epidermal Growth Factor Receptor
Abstract

Colorectal cancer (CRC) is the third most frequently diagnosed type of cancer and the second leading cause of cancer deaths worldwide. Although extensive biological heterogeneity at multiple "-omics" levels has been demonstrated, a very limited number of biomarkers are currently taken into account to guide treatment decisions in the clinic. The reason for this is partially due to the lack of validated assays suitable for routine clinical application. Building on gene expression CRC subtypes previously identified (CRCAssigner: enterocyte, goblet-like, transit-amplifying, stem-like, inflammatory; Consensus Molecular Subtypes (CMS): CMs1, CMS2, CMS3, CMS4) as potential biomarkers of clinical interest, the aims of the work presented in this thesis were: - Develop and validate assays able to stratify CRC patients into clinically meaningful subgroups based on the subtypes; - Demonstrate the potential value of the assays as companion diagnostic tools for prediction of benefit from epidermal growth factor receptor (EGFR) targeted drugs cetuximab and panitumumab. A total of 825 clinically annotated CRC samples were analysed. A gene expression assay for nCounter platform (NanoString Technologies) was developed to classify CRC samples into CMS. A second assay was developed to integrate the first CMS assay into a previously validated assay for CRCAssigner classification. The integrated assays enabled the simultaneous classification of samples into CRCAssigner and CMS subtypes. The accuracy of the assays was assessed in both fresh-frozen and formalin-fixed paraffin embedded samples. Orthogonal validation of the results was performed using matched RNAseq data and by confirming known subtype-specific associations with clinico-pathological features. Assay detection of similar biological features in multiple Caucasian and Asian populations was demonstrated. Finally, the potential of the assays as companion diagnostic for anti-EGFR benefit prediction was demonstrated in a retrospective cohort; the results were validated in samples prospectively collected from patients who received anti-EGFR monotherapy within an international phase III clinical trial.

Published
2020

7. Petosemtamab (MCLA-158) with pembrolizumab as first-line (1L) treatment of recurrent/metastatic (r/m) head and neck squamous cell carcinoma (HNSCC): Phase 2 study.

Author

Fayette, Jerome, primary, Clatot, Florian, additional, Brana, Irene, additional, Saada, Esma, additional, van Herpen, Carla M.L.-, additional, Mazard, Thibault, additional, Perez, Cesar Augusto, additional, Tabernero, Josep, additional, Le Tourneau, Christophe, additional, Hollebecque, Antoine, additional, Arrazubi Arrula, Virginia, additional, Fontana, Elisa, additional, Kato, Shumei, additional, Sacco, Assuntina G., additional, Harandi, Amir, additional, De Boer, J.P., additional, Hellyer, Jessica, additional, Pennella, Eduardo, additional, Joe, Andrew K., additional, and Daste, Amaury, additional

Published
2024
Full Text
View/download PDF

8. Supplementary Figure S5 from Circulating microRNA Analysis in a Prospective Co-clinical Trial Identifies MIR652–3p as a Response Biomarker and Driver of Regorafenib Resistance Mechanisms in Colorectal Cancer

Author

Hedayat, Somaieh, primary, Cascione, Luciano, primary, Cunningham, David, primary, Schirripa, Marta, primary, Lampis, Andrea, primary, Hahne, Jens C., primary, Tunariu, Nina, primary, Hong, Sung Pil, primary, Marchetti, Silvia, primary, Khan, Khurum, primary, Fontana, Elisa, primary, Angerilli, Valentina, primary, Delrieux, Mia, primary, Nava Rodrigues, Daniel, primary, Procaccio, Letizia, primary, Rao, Sheela, primary, Watkins, David, primary, Starling, Naureen, primary, Chau, Ian, primary, Braconi, Chiara, primary, Fotiadis, Nicos, primary, Begum, Ruwaida, primary, Guppy, Naomy, primary, Howell, Louise, primary, Valenti, Melanie, primary, Cribbes, Scott, primary, Kolozsvari, Bernadett, primary, Kirkin, Vladimir, primary, Lonardi, Sara, primary, Ghidini, Michele, primary, Passalacqua, Rodolfo, primary, Elghadi, Raghad, primary, Magnani, Luca, primary, Pinato, David J., primary, Di Maggio, Federica, primary, Ghelardi, Filippo, primary, Sottotetti, Elisa, primary, Vetere, Guglielmo, primary, Ciracì, Paolo, primary, Vlachogiannis, Georgios, primary, Pietrantonio, Filippo, primary, Cremolini, Chiara, primary, Cortellini, Alessio, primary, Loupakis, Fotios, primary, Fassan, Matteo, primary, and Valeri, Nicola, primary

Published
2024
Full Text
View/download PDF

9. Supplementary Video S1 from Circulating microRNA Analysis in a Prospective Co-clinical Trial Identifies MIR652–3p as a Response Biomarker and Driver of Regorafenib Resistance Mechanisms in Colorectal Cancer

Author

Hedayat, Somaieh, primary, Cascione, Luciano, primary, Cunningham, David, primary, Schirripa, Marta, primary, Lampis, Andrea, primary, Hahne, Jens C., primary, Tunariu, Nina, primary, Hong, Sung Pil, primary, Marchetti, Silvia, primary, Khan, Khurum, primary, Fontana, Elisa, primary, Angerilli, Valentina, primary, Delrieux, Mia, primary, Nava Rodrigues, Daniel, primary, Procaccio, Letizia, primary, Rao, Sheela, primary, Watkins, David, primary, Starling, Naureen, primary, Chau, Ian, primary, Braconi, Chiara, primary, Fotiadis, Nicos, primary, Begum, Ruwaida, primary, Guppy, Naomy, primary, Howell, Louise, primary, Valenti, Melanie, primary, Cribbes, Scott, primary, Kolozsvari, Bernadett, primary, Kirkin, Vladimir, primary, Lonardi, Sara, primary, Ghidini, Michele, primary, Passalacqua, Rodolfo, primary, Elghadi, Raghad, primary, Magnani, Luca, primary, Pinato, David J., primary, Di Maggio, Federica, primary, Ghelardi, Filippo, primary, Sottotetti, Elisa, primary, Vetere, Guglielmo, primary, Ciracì, Paolo, primary, Vlachogiannis, Georgios, primary, Pietrantonio, Filippo, primary, Cremolini, Chiara, primary, Cortellini, Alessio, primary, Loupakis, Fotios, primary, Fassan, Matteo, primary, and Valeri, Nicola, primary

Published
2024
Full Text
View/download PDF

10. Supplementary Tables S1-S19 from Circulating microRNA Analysis in a Prospective Co-clinical Trial Identifies MIR652–3p as a Response Biomarker and Driver of Regorafenib Resistance Mechanisms in Colorectal Cancer

Author

Hedayat, Somaieh, primary, Cascione, Luciano, primary, Cunningham, David, primary, Schirripa, Marta, primary, Lampis, Andrea, primary, Hahne, Jens C., primary, Tunariu, Nina, primary, Hong, Sung Pil, primary, Marchetti, Silvia, primary, Khan, Khurum, primary, Fontana, Elisa, primary, Angerilli, Valentina, primary, Delrieux, Mia, primary, Nava Rodrigues, Daniel, primary, Procaccio, Letizia, primary, Rao, Sheela, primary, Watkins, David, primary, Starling, Naureen, primary, Chau, Ian, primary, Braconi, Chiara, primary, Fotiadis, Nicos, primary, Begum, Ruwaida, primary, Guppy, Naomy, primary, Howell, Louise, primary, Valenti, Melanie, primary, Cribbes, Scott, primary, Kolozsvari, Bernadett, primary, Kirkin, Vladimir, primary, Lonardi, Sara, primary, Ghidini, Michele, primary, Passalacqua, Rodolfo, primary, Elghadi, Raghad, primary, Magnani, Luca, primary, Pinato, David J., primary, Di Maggio, Federica, primary, Ghelardi, Filippo, primary, Sottotetti, Elisa, primary, Vetere, Guglielmo, primary, Ciracì, Paolo, primary, Vlachogiannis, Georgios, primary, Pietrantonio, Filippo, primary, Cremolini, Chiara, primary, Cortellini, Alessio, primary, Loupakis, Fotios, primary, Fassan, Matteo, primary, and Valeri, Nicola, primary

Published
2024
Full Text
View/download PDF

11. Supplementary Methods S1 from Circulating microRNA Analysis in a Prospective Co-clinical Trial Identifies MIR652–3p as a Response Biomarker and Driver of Regorafenib Resistance Mechanisms in Colorectal Cancer

Author

Hedayat, Somaieh, primary, Cascione, Luciano, primary, Cunningham, David, primary, Schirripa, Marta, primary, Lampis, Andrea, primary, Hahne, Jens C., primary, Tunariu, Nina, primary, Hong, Sung Pil, primary, Marchetti, Silvia, primary, Khan, Khurum, primary, Fontana, Elisa, primary, Angerilli, Valentina, primary, Delrieux, Mia, primary, Nava Rodrigues, Daniel, primary, Procaccio, Letizia, primary, Rao, Sheela, primary, Watkins, David, primary, Starling, Naureen, primary, Chau, Ian, primary, Braconi, Chiara, primary, Fotiadis, Nicos, primary, Begum, Ruwaida, primary, Guppy, Naomy, primary, Howell, Louise, primary, Valenti, Melanie, primary, Cribbes, Scott, primary, Kolozsvari, Bernadett, primary, Kirkin, Vladimir, primary, Lonardi, Sara, primary, Ghidini, Michele, primary, Passalacqua, Rodolfo, primary, Elghadi, Raghad, primary, Magnani, Luca, primary, Pinato, David J., primary, Di Maggio, Federica, primary, Ghelardi, Filippo, primary, Sottotetti, Elisa, primary, Vetere, Guglielmo, primary, Ciracì, Paolo, primary, Vlachogiannis, Georgios, primary, Pietrantonio, Filippo, primary, Cremolini, Chiara, primary, Cortellini, Alessio, primary, Loupakis, Fotios, primary, Fassan, Matteo, primary, and Valeri, Nicola, primary

Published
2024
Full Text
View/download PDF

13. Results From First-in-Human Phase I Dose-Escalation Study of a Novel Bicycle Toxin Conjugate Targeting EphA2 (BT5528) in Patients With Advanced Solid Tumors.

Author

Bashir, Babar, Wang, Judy S., Falchook, Gerald, Fontana, Elisa, Arkenau, Hendrik-Tobias, Carter, Louise, Galot, Rachel, Basu, Bristi, Greystoke, Alastair, Subbiah, Vivek, Richardson, Debra L., Orr, Hanna, Bennett, Gavin, Sharma, Rajiv, Xu, Hongmei, Paganoni, Paola, Xu, Cong, Campbell, Carly, and McKean, Meredith

Published
2024
Full Text
View/download PDF

14. Ataxia telangiectasia and Rad3-related (ATR) inhibitor camonsertib dose optimization in patients with biomarker-selected advanced solid tumors (TRESR study).

Author

Fontana, Elisa, Rosen, Ezra, Lee, Elizabeth K, Højgaard, Martin, Mettu, Niharika B, Lheureux, Stephanie, Carneiro, Benedito A, Cote, Gregory M, Carter, Louise, Plummer, Ruth, Mahalingam, Devalingam, Fretland, Adrian J, Schonhoft, Joseph D, Silverman, Ian M, Wainszelbaum, Marisa, Xu, Yi, Ulanet, Danielle, Koehler, Maria, and Yap, Timothy A

Subjects
*CIRCULATING tumor DNA, *DNA repair, *ATAXIA telangiectasia, *BIOMARKERS, *ADVERSE health care events
Abstract

Background Camonsertib is a selective oral inhibitor of ataxia telangiectasia and Rad3-related (ATR) kinase with demonstrated efficacy in tumors with DNA damage response gene deficiencies. On-target anemia is the main drug-related toxicity typically manifesting after the period of dose-limiting toxicity evaluation. Thus, dose and schedule optimization requires extended follow-up to assess prolonged treatment effects. Methods Long-term safety, tolerability, and antitumor efficacy of 3 camonsertib monotherapy dosing regimens were assessed in the TRESR study dose-optimization phase: 160 mg once daily (QD) 3 days on, 4 days off (160 3/4; the preliminary recommended Phase II dose [RP2D]) and two step-down groups of 120 mg QD 3/4 (120 3/4) and 160 mg QD 3/4, 2 weeks on, 1 week off (160 3/4, 2/1w). Safety endpoints included incidence of treatment-related adverse events (TRAEs), dose modifications, and transfusions. Efficacy endpoints included overall response rate, clinical benefit rate, progression-free survival, and circulating tumor DNA (ctDNA)-based molecular response rate. Results The analysis included 119 patients: 160 3/4 (n = 67), 120 3/4 (n = 25), and 160 3/4, 2/1w (n = 27) treated up to 117.1 weeks as of the data cutoff. The risk of developing grade 3 anemia was significantly lower in the 160 3/4, 2/1w group compared with the preliminary RP2D group (hazard ratio = 0.23, 2-sided P  = .02), translating to reduced transfusion and dose reduction requirements. The intermittent weekly schedule did not compromise antitumor activity. Conclusion The 160 3/4, 2/1w dose was established as an optimized regimen for future camonsertib monotherapy studies offering a substantial reduction in the incidence of anemia without any compromise to efficacy. Clinical Trial ID NCT04497116. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

16. Derazantinib alone and with atezolizumab in metastatic urothelial carcinoma with activating FGFR aberrations

Author

Necchi, Andrea, primary, Ramlau, Rodryg, additional, Falcón González, Alejandro, additional, Chaudhry, Arvind, additional, Todenhöfer, Tilman, additional, Tahbaz, Rana, additional, Fontana, Elisa, additional, Giannatempo, Patrizia, additional, Deville, Jean-Laurent, additional, Pouessel, Damien, additional, Yoon, Shinkyo, additional, Powles, Thomas, additional, Bernat, Mathieu, additional, Häckl, Manuel, additional, Marszewska, Michalina, additional, McKernan, Phil, additional, Saulay, Mikael, additional, Scaleia, Federica, additional, Engelhardt, Marc, additional, Loriot, Yohann, additional, Siefker-Radtke, Arlene, additional, and De Santis, Maria, additional

Published
2024
Full Text
View/download PDF

17. Circulating microRNA Analysis in a Prospective Co-clinical Trial Identifies MIR652–3p as a Response Biomarker and Driver of Regorafenib Resistance Mechanisms in Colorectal Cancer

Author

Hedayat, Somaieh, primary, Cascione, Luciano, additional, Cunningham, David, additional, Schirripa, Marta, additional, Lampis, Andrea, additional, Hahne, Jens C., additional, Tunariu, Nina, additional, Hong, Sung Pil, additional, Marchetti, Silvia, additional, Khan, Khurum, additional, Fontana, Elisa, additional, Angerilli, Valentina, additional, Delrieux, Mia, additional, Nava Rodrigues, Daniel, additional, Procaccio, Letizia, additional, Rao, Sheela, additional, Watkins, David, additional, Starling, Naureen, additional, Chau, Ian, additional, Braconi, Chiara, additional, Fotiadis, Nicos, additional, Begum, Ruwaida, additional, Guppy, Naomy, additional, Howell, Louise, additional, Valenti, Melanie, additional, Cribbes, Scott, additional, Kolozsvari, Bernadett, additional, Kirkin, Vladimir, additional, Lonardi, Sara, additional, Ghidini, Michele, additional, Passalacqua, Rodolfo, additional, Elghadi, Raghad, additional, Magnani, Luca, additional, Pinato, David J., additional, Di Maggio, Federica, additional, Ghelardi, Filippo, additional, Sottotetti, Elisa, additional, Vetere, Guglielmo, additional, Ciracì, Paolo, additional, Vlachogiannis, Georgios, additional, Pietrantonio, Filippo, additional, Cremolini, Chiara, additional, Cortellini, Alessio, additional, Loupakis, Fotios, additional, Fassan, Matteo, additional, and Valeri, Nicola, additional

Published
2024
Full Text
View/download PDF

18. Data from Development of a Practical Nomogram for Personalized Anemia Management in Patients Treated with Ataxia Telangiectasia and Rad3-related Inhibitor Camonsertib

Author

Rosen, Ezra, primary, Yap, Timothy A., primary, Lee, Elizabeth K., primary, Højgaard, Martin, primary, Mettu, Niharika B., primary, Lheureux, Stephanie, primary, Carneiro, Benedito A., primary, Plummer, Ruth, primary, Fretland, Adrian J., primary, Ulanet, Danielle, primary, Xu, Yi, primary, McDougall, Robin, primary, Koehler, Maria, primary, and Fontana, Elisa, primary

Published
2024
Full Text
View/download PDF

19. Supplementary Fig. S2 from Development of a Practical Nomogram for Personalized Anemia Management in Patients Treated with Ataxia Telangiectasia and Rad3-related Inhibitor Camonsertib

Author

Rosen, Ezra, primary, Yap, Timothy A., primary, Lee, Elizabeth K., primary, Højgaard, Martin, primary, Mettu, Niharika B., primary, Lheureux, Stephanie, primary, Carneiro, Benedito A., primary, Plummer, Ruth, primary, Fretland, Adrian J., primary, Ulanet, Danielle, primary, Xu, Yi, primary, McDougall, Robin, primary, Koehler, Maria, primary, and Fontana, Elisa, primary

Published
2024
Full Text
View/download PDF

20. Supplementary Table S1 from Development of a Practical Nomogram for Personalized Anemia Management in Patients Treated with Ataxia Telangiectasia and Rad3-related Inhibitor Camonsertib

Author

Rosen, Ezra, primary, Yap, Timothy A., primary, Lee, Elizabeth K., primary, Højgaard, Martin, primary, Mettu, Niharika B., primary, Lheureux, Stephanie, primary, Carneiro, Benedito A., primary, Plummer, Ruth, primary, Fretland, Adrian J., primary, Ulanet, Danielle, primary, Xu, Yi, primary, McDougall, Robin, primary, Koehler, Maria, primary, and Fontana, Elisa, primary

Published
2024
Full Text
View/download PDF

21. MIR21-induced loss of junctional adhesion molecule A promotes activation of oncogenic pathways, progression and metastasis in colorectal cancer

Author

Lampis, Andrea, Hahne, Jens C., Gasparini, Pierluigi, Cascione, Luciano, Hedayat, Somaieh, Vlachogiannis, Georgios, Murgia, Claudio, Fontana, Elisa, Edwards, Joanne, Horgan, Paul G., Terracciano, Luigi, Sansom, Owen J., Martins, Carlos D., Kramer-Marek, Gabriela, Croce, Carlo M., Braconi, Chiara, Fassan, Matteo, and Valeri, Nicola

Published
2021
Full Text
View/download PDF

25. Come cambia l’apprendimento nella formazione degli Educatori professionali.

Author

Costa, Andrea, Rebaicini, Alberto, and Fontana, Elisa

Subjects
YOUNG adults, PROFESSIONAL identity, PROFESSIONAL education, EXPERIENTIAL learning, ADULTS, EDUCATORS
Abstract

Copyright of Journal of Health Care Education in Practice is the property of Padova University Press and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Published
2024
Full Text
View/download PDF

26. Detection of postoperative plasma circulating tumour DNA and lack of CDX2 expression as markers of recurrence in patients with localised colon cancer

Author

Tarazona, Noelia, Gimeno-Valiente, Francisco, Gambardella, Valentina, Huerta, Marisol, Roselló, Susana, Zuniga, Sheila, Calon, Alexandre, Carbonell-Asins, Juan Antonio, Fontana, Elisa, Martinez-Ciarpaglini, Carolina, Eason, Katherine, Rentero-Garrido, Pilar, Fleitas, Tania, Papaccio, Federica, Moro-Valdezate, David, Nyamundanda, Gift, Castillo, Josefa, Espí, Alejandro, Sadanandam, Anguraj, Roda, Desamparados, and Cervantes, Andrés

Published
2020
Full Text
View/download PDF

29. Development of a Practical Nomogram for Personalized Anemia Management in Patients Treated with Ataxia Telangiectasia and Rad3-related Inhibitor Camonsertib

Author

Rosen, Ezra, primary, Yap, Timothy A., additional, Lee, Elizabeth K., additional, Højgaard, Martin, additional, Mettu, Niharika B., additional, Lheureux, Stephanie, additional, Carneiro, Benedito A., additional, Plummer, Ruth, additional, Fretland, Adrian J., additional, Ulanet, Danielle, additional, Xu, Yi, additional, McDougall, Robin, additional, Koehler, Maria, additional, and Fontana, Elisa, additional

Published
2023
Full Text
View/download PDF

30. Benefit from anti-EGFRs in RAS and BRAF wild-type metastatic transverse colon cancer: a clinical and molecular proof of concept study

Author

Cremolini, Chiara, Benelli, Matteo, Fontana, Elisa, Pagani, Filippo, Rossini, Daniele, Fucà, Giovanni, Busico, Adele, Conca, Elena, Di Donato, Samantha, Loupakis, Fotios, Schirripa, Marta, Lonardi, Sara, Borelli, Beatrice, Ongaro, Elena, Eason, Katherine, Morano, Federica, Casagrande, Mariaelena, Fassan, Matteo, Sadanandam, Anguraj, de Braud, Filippo, Falcone, Alfredo, and Pietrantonio, Filippo

Published
2019
Full Text
View/download PDF

32. Right frontal cingulate cortex mediates the effect of prenatal complications on youth internalizing behaviors.

Author

Brambilla, Paolo, primary, Maggioni, Eleonora, additional, Pigoni, Alessandro, additional, Fontana, Elisa, additional, Delvecchio, Giuseppe, additional, Bonivento, Carolina, additional, Bianchi, Valentina, additional, Mauri, Maddalena, additional, Bellina, Monica, additional, Girometti, Rossano, additional, Agarwal, Nivedita, additional, and Nobile, Maria, additional

Published
2023
Full Text
View/download PDF

34. Abstract CT265: Phase 1 dose-escalation study of SGN-TGT monotherapy in patients with advanced malignancies

Author

Cabanas, Elena Garralda, primary, Fontana, Elisa, additional, Oberoi, Honey Kumar, additional, Uboha, Nataliya V., additional, Dumbrava, Ecaterina E., additional, Calvo, Emiliano, additional, Curigliano, Giuseppe, additional, Davar, Diwakar, additional, Keenan, Bridget K., additional, Lam, Vincent K., additional, Manda, Sudhir, additional, Mehta, Amitkuma, additional, Minchom, Anna, additional, Moskowitz, Alison, additional, Paluri, Ravi, additional, Ribrag, Vincent, additional, Richards, Donald, additional, Siu, Lillian, additional, Swiecicki, Paul, additional, Wise-Draper, Trisha, additional, Zain, Jasmine, additional, Forero-Torres, Andres, additional, Xu, Ping, additional, and Ansell, Stephen, additional

Published
2023
Full Text
View/download PDF

35. Abstract CT018: Safety and efficacy of three PARP inhibitors (PARPi) combined with the ataxia telangiectasia- and Rad3-related kinase inhibitor (ATRi) camonsertib in patients (pts) with solid tumors harboring DNA damage response (DDR) alterations

Author

Yap, Timothy A., primary, Yadav, Siddhartha, additional, Herzberg, Benjamin, additional, Carneiro, Benedito A., additional, Fontana, Elisa, additional, Højgaard, Martin, additional, Pishvaian, Michael J., additional, Plummer, Ruth, additional, Werner, Theresa L., additional, Sahai, Vaibhav, additional, Lheureux, Stephanie, additional, Lee, Elizabeth K., additional, Mettu, Niharika B., additional, Cote, Gregory M., additional, Schonhoft, Joseph D., additional, Rimkunas, Victoria, additional, Silverman, Ian M., additional, Wainszelbaum, Marisa, additional, Peltz, Gerson, additional, Fretland, Adrian J., additional, Fei, Kezhen, additional, Ulanet, Danielle, additional, Kim, Insil, additional, Koehler, Maria, additional, Rosen, Ezra, additional, and Cecchini, Michael, additional

Published
2023
Full Text
View/download PDF

36. Abstract CT012: Clinical activity of MCLA-158 (petosemtamab), an IgG1 bispecific antibody targeting EGFR and LGR5, in advanced head and neck squamous cell cancer (HNSCC)

Author

Cohen, Ezra E., primary, Fayette, Jérôme, additional, Daste, Amaury, additional, Even, Caroline, additional, Tourneau, Christophe Le, additional, Brana, Irene, additional, Saada, Esma, additional, Fontana, Elisa, additional, Iglesias, Lara, additional, Kato, Shumei, additional, Garcia-Carbonero, Rocio, additional, Tabernero, Josep, additional, Argilés, Guillem, additional, Magin, Marina, additional, Shen, Yu-Ming, additional, de Leeuw, Renée, additional, Bekradda, Mohamed, additional, Pennella, Eduardo, additional, Wasserman, Ernesto, additional, Stalbovskaya, Viktoriya, additional, van Bueren, Jeroen Lammerts, additional, Jain, Lokesh, additional, Joe, Andrew, additional, and Hollebecque, Antoine, additional

Published
2023
Full Text
View/download PDF

37. Abstract 6770: Spatial characterization of immune microenvironment from early onset metastatic colorectal cancer (EOmCRC) showed a dual prognostic role for IDO1 expression

Author

Nagaraju, Raghavendar Thyagaraja, primary, Franczak, Jakub, additional, Möhler, Markus, additional, Fontana, Elisa, additional, Giraut, Anne, additional, Dirix, Lieve, additional, Casas-Martin, Jose, additional, Borelli, Beatrice, additional, Lordick, Florian, additional, Smith, Elizabeth, additional, Tejpar, Sabine, additional, Folprecht, Gunnar, additional, and Barriuso, Jorge, additional

Published
2023
Full Text
View/download PDF

38. Supplementary Data from ATR Inhibition Potentiates the Radiation-induced Inflammatory Tumor Microenvironment

Author

Dillon, Magnus T., primary, Bergerhoff, Katharina F., primary, Pedersen, Malin, primary, Whittock, Harriet, primary, Crespo-Rodriguez, Eva, primary, Patin, Emmanuel C., primary, Pearson, Alex, primary, Smith, Henry G., primary, Paget, James T.E., primary, Patel, Radhika R., primary, Foo, Shane, primary, Bozhanova, Galabina, primary, Ragulan, Chanthirika, primary, Fontana, Elisa, primary, Desai, Krisha, primary, Wilkins, Anna C., primary, Sadanandam, Anguraj, primary, Melcher, Alan, primary, McLaughlin, Martin, primary, and Harrington, Kevin J., primary

Published
2023
Full Text
View/download PDF

39. BT8009-100: A phase I/II study of novel bicyclic peptide and MMAE conjugate BT8009 in patients (pts) with advanced malignancies associated with nectin-4 expression, including urothelial cancer (UC).

Author

Baldini, Capucine, primary, Goldschmidt, Vincent, additional, Brana, Irene, additional, Doger, Bernard, additional, Italiano, Antoine, additional, Cousin, Sophie, additional, Falchook, Gerald Steven, additional, Necchi, Andrea, additional, Reig, Oscar, additional, Carter, Louise, additional, Fontana, Elisa, additional, Verlingue, Loic, additional, Hazard, Sebastien, additional, Dickson, Amy, additional, Xu, Cong, additional, Xu, Hongmei, additional, Sharma, Rajiv, additional, Smethurst, Dominic, additional, and McKean, Meredith, additional

Published
2023
Full Text
View/download PDF

42. Analytical Validation of Multiplex Biomarker Assay to Stratify Colorectal Cancer into Molecular Subtypes

Author

Ragulan, Chanthirika, Eason, Katherine, Fontana, Elisa, Nyamundanda, Gift, Tarazona, Noelia, Patil, Yatish, Poudel, Pawan, Lawlor, Rita T., Del Rio, Maguy, Koo, Si-Lin, Tan, Wah-Siew, Sclafani, Francesco, Begum, Ruwaida, Teixeira Mendes, Larissa S., Martineau, Pierre, Scarpa, Aldo, Cervantes, Andrés, Tan, Iain Beehuat, Cunningham, David, and Sadanandam, Anguraj

Published
2019
Full Text
View/download PDF

43. Yoga‐integrated psychotherapy for emotion dysregulation: A pilot study.

Author

Childs‐Fegredo, Jasmine, Fontana, Elisa, Moran, Mary, and Faulkner, Paul

Subjects
*ANXIETY treatment, *WELL-being, *THERAPEUTICS, *PILOT projects, *ANALYSIS of variance, *YOGA, *ATTITUDE (Psychology), *SELF-evaluation, *INTERVIEWING, *QUANTITATIVE research, *TREATMENT effectiveness, *PATIENTS' attitudes, *QUALITATIVE research, *AFFECTIVE disorders, *MENTAL depression, *RESEARCH funding, *EMOTION regulation, *THEMATIC analysis, *PSYCHOTHERAPY, *PSYCHOLOGICAL resilience
Abstract

Aims & Objectives: Yoga has been evidenced as beneficial for physical and mental health. This study sought to pilot the acceptability and feasibility of a yoga‐integrated psychotherapy (YiP) intervention, aimed at alleviating difficulties in emotion regulation. A further aim was to explore the perceived effectiveness of YiP in alleviating depression, anxiety and improving well‐being. Methods: Seven participants who scored significantly on the Difficulties in Emotion Dysregulation Scale (DERS) took part in a psychological assessment session followed by six weekly one hr therapy sessions. Participants completed self‐report measures in each session to quantify the effects of each YiP session on emotion regulation, well‐being, depression and anxiety. Following seven sessions, five participants completed qualitative follow‐up interviews to explore subjective experiences of YiP and any perceived impacts. Findings: An ANOVA that contained data from seven participants who completed all six sessions revealed that DERS scores were significantly lower, and well‐being scores were significantly higher, at both mid and end‐points than at baseline. Thematic analysis of qualitative interviews identified five themes: "YiP assists the client's psychological and emotional processing," "YiP improves insight and focus," "YiP is culturally sensitive," "the body facilitates regulation and resilience" and "YiP is acceptable & impactful." Conclusion: The study presents promising findings for the integration of yoga into psychotherapeutic practice and indicates that YiP may have beneficial effects on emotion regulation and psychological well‐being. Future research should use randomised controlled methodologies to examine the ability of YiP to alleviate a wide range of affective symptoms using a larger sample of participants. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

47. 1173 ST101, a peptide antagonist of novel I/O target CEBPβ, reprograms MDSC polarization and decreases tumor-associated Tregs, suggesting an immune component to observed clinical responses

Author

Scuoppo, Claudio, primary, Falchook, Gerald, additional, Fontana, Elisa, additional, Williams, Anja, additional, Lakhani, Nehal, additional, Evans, Jeff, additional, Iwamoto, Fabio, additional, McKean, Meredith, additional, Symeonides, Stefan, additional, McLaren, Alistair, additional, Henry, Jason, additional, Capiaux, Gina, additional, Michel, Robert, additional, Kaesshaefer, Stephen, additional, Bexon, Alice, additional, and Rotolo, Jim, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results